Neoplasia (Oncology BASKET)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Oncology BASKET).php on line 2
Neoplasia (Oncology BASKET)

LE WE PMID CA

Neoplasia (Oncology BASKET)

2041

Neubildung (Onkologie allg)

Heparin

History of medicine

Irgendwie seltsame Erkenntnisse

Laboratory animal (Zebrafish)

Medical ethics

Neoplasia (Oncology BASKET)

Neoplasia (Screening)

Neoplasia (Tumor biology and immunology)

1964 1	PROGRESS IN CHEMOTHERAPY OF CANCER. [14163957] Bull World Health Organ 30(-): 327-41 (1964)
1990 2	The plateau in cytotoxic cancer drug discovery. [2204674] J Med 21(3-4): 143-63 (1990)
2002 3	Oncologic emergencies for the internist. [11890211] Cleve Clin J Med 69(3): 209-10, 213-4, 216-7 passim (2002)
2008 4	Techniques of interventional tumor therapy. [19471636] Dtsch Arztebl Int 105(38): 646-53 (2008)
2006 5	The use of clostridial spores for cancer treatment. [16907807] J Appl Microbiol 101(3): 571-8 (2006)
1967 6	A theory of the action of cancer chemotherapeutic drugs. [5340665] Clin Exp Immunol 2(3): 361-73 (1967)
2010 7	A new paradigm for cancer therapeutics development. [20587327] BMB Rep 43(6): 383-8 (2010)
2006 8	Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of therapeutic approaches. [17116284] Folia Biol (Praha) 52(4): 119-36 (2006)
1955 9	Cancer research; a review. [13259411] Ann R Coll Surg Engl 17(3): 184-93 (1955)
1949 10	Chemotherapeutic drugs; a review. [15398658] Ann R Coll Surg Engl 5(6): 367-93 (1949)
1990 11	Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology. [2194440] Ann Surg 212(1): 3-13 (1990)
1985 12	Need for immunologic stimulators during immunosuppression produced by major cancer surgery. [3893336] Ann Surg 202(1): 9-20 (1985)
2010 13	Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. [20307299] BMC Cancer 10(-): 105 (2010)
2008 14	Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. [18373855] BMC Cancer 8(-): 84 (2008)
2003 15	Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. [14588079] BMC Cancer 3(-): 28 (2003)
2003 16	Measuring response in solid tumors: comparison of RECIST and WHO response criteria. [14623923] Jpn J Clin Oncol 33(10): 533-7 (2003)
2000 17	On the immunomodulating effects of anti-cancer drugs and their therapeutic exploitation. [11155915] Jpn J Clin Oncol 30(11): 469-71 (2000)
1997 18	Inequalities in survival from cancer. [9152471] Tumori 83(1): 505-7 (1997)
2005 19	A review of the past, present, and future directions of neoplasia. [16354585] Neoplasia 7(12): 1039-46 (2005)
2007 20	Salient features of hematological diseases. [17311824] Ann Oncol 18 Suppl 1(-): i54-i64 (2007)
2007 21	Hematological emergencies. [17311822] Ann Oncol 18 Suppl 1(-): i45-i48 (2007)
2006 22	Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). [16410361] Ann Oncol 17(7): 1051-9 (2006)
2004 23	Opportunistic infections in patients with cancer. [15477331] Ann Oncol 15 Suppl 4(-): iv329-35 (2004)
2004 24	Oncological emergencies. [15477325] Ann Oncol 15 Suppl 4(-): iv299-306 (2004)
1999 25	High-dose chemotherapy: is it standard management for any common solid tumor? [10586330] Ann Oncol 10(10): 1145-61 (1999)
2007 26	Minimal access cancer management. [17507440] CA Cancer J Clin 57(3): 130-46 (2007)
2006 27	Preventing occupational exposures to antineoplastic drugs in health care settings. [17135692] CA Cancer J Clin 56(6): 354-65 (2006)
2005 28	Use of antioxidants during chemotherapy and radiotherapy should be avoided. [16166076] CA Cancer J Clin 55(5): 319-21 (2005)
2004 29	Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. [15253918] CA Cancer J Clin 54(4): 208-36 (2004)
1992 30	Long-term survivors of childhood cancer: evaluation and identification of sequelae of treatment. [1515966] CA Cancer J Clin 42(5): 263-82 (1992)
1992 31	Neuropsychological and psychosocial effects of childhood leukemia and its treatment. [1515967] CA Cancer J Clin 42(5): 283-95 (1992)
1992 32	Late adverse effects of treatment among patients cured of cancer during childhood. [1515965] CA Cancer J Clin 42(5): 261-2 (1992)
1987 33	Metabolic oncologic emergencies. [3115508] CA Cancer J Clin 37(5): 302-20 (1987)
1985 34	Delayed consequences of therapy for childhood cancer. [3930013] CA Cancer J Clin 35(5): 271-86 (1985)
1983 35	Is there a cancer-prone personality? [6404522] CA Cancer J Clin 33(3): 145-53 (1983)
1979 36	The pathology of tumors. Part II: Diagnostic techniques. [110397] CA Cancer J Clin 29(1): 22-39 (1979)
2008 37	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. [18798533] Cancer 113(7 Suppl): 1933-52 (2008)
2008 38	Systemic cancer therapy: evolution over the last 60 years. [18798529] Cancer 113(7 Suppl): 1857-87 (2008)
2007 39	Diagnosis delays in childhood cancer: a review. [17620277] Cancer 110(4): 703-13 (2007)
2003 40	Cancer chronotherapy: principles, applications, and perspectives. [12491517] Cancer 97(1): 155-69 (2003)
2000 41	Molecular biology in cytopathology: current applications and future directions. [10692210] Cancer 90(1): 1-9 (2000)
1999 42	Results from a historical survey of the survival of cancer patients given Di Bella multitherapy. [10570444] Cancer 86(10): 2143-9 (1999)
2006 43	Unconventional anticancer agents: a systematic review of clinical trials. [16382123] J Clin Oncol 24(1): 136-40 (2006)
2007 44	Surviving antioxidant supplements. [17505064] J Natl Cancer Inst 99(10): 742-3 (2007)
2000 45	New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. [10655437] J Natl Cancer Inst 92(3): 205-16 (2000)
2000 46	Outcomes research in oncology: history, conceptual framework, and trends in the literature. [10655436] J Natl Cancer Inst 92(3): 195-204 (2000)
2000 47	Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? [10655425] J Natl Cancer Inst 92(3): 179-81 (2000)
2008 48	Cancer survivorship: a pediatric perspective. [18987046] Oncologist 13(11): 1181-92 (2008)
2007 49	Is molecular profiling ready for use in clinical decision making? [17405894] Oncologist 12(3): 301-11 (2007)
2006 50	Cancer in 15- to 29-year-olds by primary site. [16794238] Oncologist 11(6): 590-601 (2006)
1999 51	Long-term survivors of childhood cancer: the late effects of therapy. [10337370] Oncologist 4(1): 45-54 (1999)
1985 52	Curative cancer chemotherapy. [2998603] Cancer Res 45(12 Pt 1): 6523-37 (1985)
1969 53	The present status of cancer chemotherapy--a summary of papers delivered at the Cherry Hill Conference on "a critical evaluation of cancer chemotherapy". [5369696] Cancer Res 29(12): 2478-85 (1969)
1969 54	Factors pertaining to complete drug-induced remission of tumor in animals and man. [4917976] Cancer Res 29(12): 2285-91 (1969)
1969 55	The need for additional alkylating agents and antimetabolites. [4905240] Cancer Res 29(12): 2435-42 (1969)
1969 56	Endocrinologic factors in the design of more selective antitumor agents. [4905238] Cancer Res 29(12): 2412-6 (1969)
1969 57	Nutritional factors in the design of more selective antitumor agents. [4905239] Cancer Res 29(12): 2417-21 (1969)
1969 58	Reduction of toxicity in cancer chemotherapy. [4905237] Cancer Res 29(12): 2319-25 (1969)
1969 59	Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells. [4905235] Cancer Res 29(12): 2292-9 (1969)
1969 60	Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture. [4982548] Cancer Res 29(11): 1895-903 (1969)
1956 61	Control of cancers of man by endocrinologic methods; a review. [13364911] Cancer Res 16(9): 825-30 (1956)
1953 62	Microbiology and cancer therapy; a review. [13116119] Cancer Res 13(12): 821-34 (1953)
2002 63	Chemotherapy: targeting the mitochondrial cell death pathway. [12483532] Oncogene 21(57): 8786-803 (2002)
2006 64	The cancer stem cell: evidence for its origin as an injured autoreactive T cell. [16478542] Mol Cancer 5(-): 6 (2006)
1998 65	Long-term survivors of cancer. [9568780] Cancer Epidemiol Biomarkers Prev 7(4): 269-70 (1998)
2009 66	Long-term cancer survivors: research issues and care needs in a key phase of the survivorship spectrum. [19937803] Am J Hematol 84(12): 782-4 (2009)
2007 67	The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. [17408406] J Thromb Haemost 5(4): 729-37 (2007)
1969 68	Current status of the management of patients with endocrine-sensitive tumors. II. Carcinoma of the prostate, endometrium, thyroid, kidney and miscellaneous tumors. [4894628] Calif Med 110(2): 139-50 (1969)
2005 69	Renal failure associated with cancer and its treatment: an update. [15574506] J Am Soc Nephrol 16(1): 151-61 (2005)
2007 70	Our moral obligations in caring for patients with orphan cancers. [17261816] CMAJ 176(3): 297, 299 (2007)
1999 71	Complications of cancer therapy in children: a radiologist's guide. [10194780] Radiographics 19(2): 283-97 (1999)
2009 72	ESMO clinical recommendations: using the easier and faster approach to oncology guidelines. [19454468] Ann Oncol 20 Suppl 4(-): 7-9 (2009)
2010 73	Concomitant medications in cancer patients: should we be more active in their management? [19940008] Ann Oncol 21(2): 430 (2010)
2010 74	Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. [20184544] Anticancer Agents Med Chem 10(2): 137-51 (2010)
2003 75	Telomerase promoter-driven cancer gene therapy. [14508082] Cancer Biol Ther 2(4 Suppl 1): S64-70 (2003)
2003 76	Tumor-suppressing gene therapy. [14508088] Cancer Biol Ther 2(4 Suppl 1): S115-21 (2003)
2007 77	Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. [18087223] Cancer Biol Ther 6(9): 1345-54 (2007)
2005 78	Targeting TGFbeta signaling for cancer therapy. [15846079] Cancer Biol Ther 4(3): 261-6 (2005)
2009 79	Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? [19479708] Arthritis Rheum 61(6): 801-12 (2009)
2004 80	Endocrine aspects of cancer gene therapy. [14769826] Endocr Rev 25(1): 1-44 (2004)
2003 81	Peptide receptors as molecular targets for cancer diagnosis and therapy. [12920149] Endocr Rev 24(4): 389-427 (2003)
2004 82	Reanalysis of cancer drugs: old drugs, new tricks. [15173099] Clin Cancer Res 10(11): 3897-907 (2004)
2004 83	Complementary and alternative therapies for cancer. [14755017] Oncologist 9(1): 80-9 (2004)
2006 84	Complementary and alternative medicine during cancer treatment: beyond innocence. [16880232] Oncologist 11(7): 732-41 (2006)
2003 85	Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. [14669301] Cancer 98(12): 2740-1 (2003)
2002 86	Getting the right dose in cancer chemotherapy--time to stop using surface area? [11953873] Br J Cancer 86(8): 1207-8 (2002)
2002 87	How to calculate the dose of chemotherapy. [11953888] Br J Cancer 86(8): 1297-302 (2002)
2003 88	Tissue-selective therapy of cancer. [14520435] Br J Cancer 89(7): 1147-51 (2003)
2009 89	Molecular classification of solid tumours: towards pathway-driven therapeutics. [19367275] Br J Cancer 100(10): 1517-22 (2009)
2006 90	Biological response modifiers in cancer. [17415315] MedGenMed 8(4): 33 (2006)
2008 91	Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. [19088353] JAMA 300(23): 2754-64 (2008)
2001 92	Targeted therapies for killing tumor cells. [11526225] Proc Natl Acad Sci U S A 98(18): 10028-30 (2001)
2010 93	Overdiagnosis in cancer. [20413742] J Natl Cancer Inst 102(9): 605-13 (2010)
2004 94	Complementary and alternative cancer therapies: past, present and the future scenario. [15074998] Asian Pac J Cancer Prev 5(1): 3-14 (2004)
2010 95	Metabolism and cancer: an up-to-date review of a mutual connection. [21338177] Asian Pac J Cancer Prev 11(6): 1437-44 (2010)
2010 96	The importance of identifying and validating prognostic factors in oncology. [20494694] Semin Oncol 37(2): e9-18 (2010)
2010 97	Pediatric oncology. [20610196] Semin Pediatr Surg 19(3): 225-33 (2010)
2011 98	Progress of non-human primate animal models of cancers. [21341388] Dongwuxue Yanjiu 32(1): 70-80 (2011)
2009 99	Zebrafish tumor assays: the state of transplantation. [20047467] Zebrafish 6(4): 339-46 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Oncology BASKET).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Neoplasia (Oncology BASKET).php on line 92